Literature DB >> 15201704

Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia.

Maha Abdelrahman1, Edward J Sharples, Michelle C McDonald, Marika Collin, Nimesh S A Patel, Muhammad M Yaqoob, Christoph Thiemermann.   

Abstract

Here we investigate the effects of erythropoietin (EPO) on the tissue/organ injury caused by hemorrhagic shock (HS), endotoxic shock, and regional myocardial ischemia and reperfusion in anesthetized rats. Male Wistar rats were anesthetized with thiopental sodium (85 mg/kg i.p.) and subjected to hemorrhagic shock (HS; i.e., mean arterial blood pressure reduced to 45 mmHg for 90 min, followed by resuscitation with shed blood for 4 h), endotoxemia (for 6 h), or left anterior descending coronary artery occlusion (25 min) and reperfusion (2 h). HS and endotoxemia resulted in renal dysfunction and liver injury. Administration of EPO (300 IU/kg i.v., n = 10) before resuscitation abolished the renal dysfunction and liver injury in hemorrhagic, but not endotoxic, shock. HS also resulted in significant increases in the kidney of the activities of caspases 3, 8, and 9. This increase in caspase activity was not seen in HS rats treated with EPO. In cultured human proximal tubule cells, EPO concentration-dependently reduced the cell death and increase in caspase-3 activity caused by either ATP depletion (simulated ischemia) or hydrogen peroxide (oxidative stress). In the heart, administration of EPO (300 IU/kg i.v., n = 10) before reperfusion also caused a significant reduction in infarct size. In cultured rat cardiac myoblasts (H9C2 cells), EPO also reduced the increase in DNA fragmentation caused by either serum deprivation (simulated ischemia) or hydrogen peroxide (oxidative stress). We propose that the acute administration of EPO on reperfusion and/or resuscitation will reduce the tissue injury caused by ischemia-reperfusion of the heart (and other organs) and hemorrhagic shock.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15201704     DOI: 10.1097/01.shk.00001276869.21260.9d

Source DB:  PubMed          Journal:  Shock        ISSN: 1073-2322            Impact factor:   3.454


  31 in total

1.  Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial.

Authors:  Jula K Inrig; Huiman X Barnhart; Donal Reddan; Uptal D Patel; Shelly Sapp; Robert M Califf; Ajay K Singh; Lynda A Szczech
Journal:  Am J Kidney Dis       Date:  2012-04-25       Impact factor: 8.860

Review 2.  Protecting mitochondrial bioenergetic function during resuscitation from cardiac arrest.

Authors:  Raúl J Gazmuri; Jeejabai Radhakrishnan
Journal:  Crit Care Clin       Date:  2012-04       Impact factor: 3.598

Review 3.  Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward?

Authors:  Carla Cerami Hand; Michael Brines
Journal:  J Investig Med       Date:  2011-10       Impact factor: 2.895

4.  Inhibition of IκB Kinase Attenuates the Organ Injury and Dysfunction Associated with Hemorrhagic Shock.

Authors:  Regina Sordi; Fausto Chiazza; Florence L Johnson; Nimesh S A Patel; Karim Brohi; Massimo Collino; Christoph Thiemermann
Journal:  Mol Med       Date:  2015-06-18       Impact factor: 6.354

5.  Myocardial infarction: cardioprotection by erythropoietin.

Authors:  Mark I Talan; Roberto Latini
Journal:  Methods Mol Biol       Date:  2013

6.  Role of PPAR-delta in the development of zymosan-induced multiple organ failure: an experiment mice study.

Authors:  Maria Galuppo; Rosanna Di Paola; Emanuela Mazzon; Tiziana Genovese; Concetta Crisafulli; Irene Paterniti; Elisabetta Cuzzocrea; Placido Bramanti; Amar Kapoor; Christoph Thiemermann; Salvatore Cuzzocrea
Journal:  J Inflamm (Lond)       Date:  2010-02-18       Impact factor: 4.981

Review 7.  Therapeutic and predictive targets of AKI.

Authors:  R Yalavarthy; C L Edelstein
Journal:  Clin Nephrol       Date:  2008-12       Impact factor: 0.975

8.  Postmortem serum erythropoietin levels in establishing the cause of death and survival time at medicolegal autopsy.

Authors:  L Quan; B-L Zhu; T Ishikawa; T Michiue; D Zhao; D-R Li; M Ogawa; H Maeda
Journal:  Int J Legal Med       Date:  2008-08-06       Impact factor: 2.686

9.  Pretreatment with darbepoetin attenuates renal injury in a rat model of cisplatin-induced nephrotoxicity.

Authors:  Dae Eun Choi; Jin Young Jeong; Beom Jin Lim; Kang Wook Lee; Young-Tai Shin; Ki-Ryang Na
Journal:  Korean J Intern Med       Date:  2009-08-26       Impact factor: 3.165

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.